The iShares U.S. Pharmaceuticals ETF (IHE) has gained 38% over the past year despite threats from U.S. drug pricing policies like the 'most favored nation' order. The ETF benefits from dividends and strong drug pipelines, especially from major holdings like Eli Lilly and Johnson & Johnson, though it carries concentration risk with two stocks making up 42% of assets. While broader healthcare ETFs lagged, IHE's recent outperformance is driven by GLP-1 drug successes and undervalued pharma multiples. Investors near retirement may consider adding some exposure, but should be aware of policy uncertainties and the fund's narrow focus.
Incyte has signed a $120 million partnership with Genesis Molecular AI, including $80 million upfront and a $40 million equity investment, to advance AI-driven drug discovery. This deal could exceed $1 billion with future milestones and royalties, us...
Eli Lilly has filed a civil lawsuit alleging a $200 million rebate fraud scheme involving several bishops of the Church of God in Christ and a Florida mail-order pharmacy, DrugPlace. The scheme involved false claims for rebates on the diabetes drug T...
The Fidelity MSCI Health Care Index ETF (FHLC) has declined about 5% year-to-date, while the S&P 500 has risen 7%, and over five years FHLC returned 15% versus 80% for the S&P 500. FHLC tracks a broad healthcare index with 342 holdings but is heavily...
Eli Lilly demonstrates strong bullish technical indicators including price action, momentum, and relative strength, supporting a continued uptrend. Despite receiving an 'F' valuation grade, the company's growth, profitability, and upward earnings rev...
The U.S. Supreme Court declined to hear Eli Lilly's appeal, leaving a $194 million whistleblower judgment intact. The case involved allegations that Eli Lilly underreported drug pricing to reduce Medicaid rebate payments by about $61 million. The rul...
